



THE LANCET Neurology

Vol. 13 N°3 – Marzo 2014

Editorial

233 Alemtuzumab and the value of neurological research
The Lancet Neurology

Comment

234 New evidence for teriflunomide in multiple sclerosis
Bernd C Kieseier, Heinz Wiendl

235 New treatments for multiple sclerosis: at what long-term risk?
Michelle H Cameron, Dennis Bourdette

237 Rifampicin for multiple system atrophy
Gregor K Wenning, Florian Krismer, Werner Poewe

239 A new encephalitis with GABAA receptor antibodies
Lawrence J Hirsch

Corrections

240 Corrections

In Context

241 Should your patient be doing yoga?
Adrian Burton

Profile

243 Paul Krack: deeper brain stimulation
David Holmes

Lifeline

244 Thomas Leist

Focal Point

244 **Plagues and pesticides**
Steven Goodrick

Film

245 **Indian film on epilepsy busts myths**
Dinesh C Sharma

246 **News in brief**

Articles

247 **Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial**
Christian Confavreux, Paul O'Connor, Giancarlo Comi, Mark S Freedman, Aaron E Miller, Tomas P Olsson, Jerry S Wolinsky, Teresa Bagulho, Jean-Luc Delhay, Deborah Dukovic, Philippe Truffinet, Ludwig Kappos, for the TOWER Trial Group

257 **Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial**
Thomas P Leist, Giancarlo Comi, Bruce A C Cree, Patricia K Coyle, Mark S Freedman, Hans-Peter Hartung, Patrick Vermersch, Florence Casset-Semanaz, Matthew Scaramozza, on behalf of the oral cladribine for early MS (ORACLE MS) Study Group

268 **Efficacy and safety of rifampicin for multiple system atrophy: a randomised, double-blind, placebo-controlled trial**
Phillip A Low, David Robertson, Sid Gilman, Horacio Kaufmann, Wolfgang Singer, Italo Biaggioni, Roy Freeman, Susan Perlman, Robert A Hauser, William Cheshire, Stephanie Lessig, Steven Vernino, Jay Mandrekar, William D Dupont, Thomas Chelimsky, Wendy R Galpern

276 **Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies**
Mar Petit-Pedrol, Thaís Armangue, Xiaoyu Peng, Luis Bataller, Tania Cellucci, Rebecca Davis, Lindsey McCracken, Eugenia Martinez-Hernandez, Warren P Mason, Michael C Kruer, David G Ritacco, Wolfgang Grisold, Brandon F Meaney, Carmen Alcalá, Peter Sillevs-Smitt, Maarten J Titulaer, Rita Balice-Gordon, Francesc Graus, Josep Dalmau

Review

287 **Mood and behavioural effects of subthalamic stimulation in Parkinson's disease**
Anna Castrioto, Eugénie Lhommée, Elena Moro, Paul Krack

306 Cognitive and neurological aspects of sex chromosome aneuploidies
David S Hong, Allan L Reiss

319 Targeting the β secretase BACE1 for Alzheimer's disease therapy
Riqiang Yan, Robert Vassar

330 Neurobehavioural effects of developmental toxicity
Philippe Grandjean, Philip J Landrigan